SHAREHOLDER NOTICE: Goldberg Law PC Announces Securities Class Action Lawsuit against CytRx Corp. & Encourages Investors with...
13 August 2016 - 1:10AM
Business Wire
Goldberg Law PC (the “Firm”) announces that a class action
lawsuit has been filed against CytRx Corporation (“CytRx” or the
“Company”) (Nasdaq: CYTR). Investors who purchased or otherwise
acquired shares between November 18, 2014 and June 11, 2016 (the
“Class Period”) are encouraged to contact the Firm in advance of
the September 23, 2016 lead plaintiff motion
deadline.
If you are a shareholder who suffered a loss during the Class
Period, click here to participate. In addition, we advise
you to contact Michael Goldberg or Brian Schall, of Goldberg Law
PC, 1999 Avenue of the Stars, Suite 1100, Los Angeles, CA 90067, at
800-977-7401, to discuss your rights without cost to you. You can
also reach us through the firm’s website at
http://www.Goldberglawpc.com, or by email at
info@goldberglawpc.com.
The class in this case has not yet been certified, and until
certification occurs, you are not represented by an attorney. If
you choose to take no action, you can remain an absent class
member.
According to the complaint, CytRx made materially false and
misleading statements and/or failed to disclose material facts,
specifically: that the clinical hold placed on the Phase 3 trial of
aldoxorubicin for soft tissue sarcomas would prevent enough
follow-up for patients involved in the study; that nearly half of
all patients would be excluded from the data since the study was
disturbed by a partial clinical hold; that the Company would likely
conduct a second analysis as a result; and that the results of the
trial could be materially affected and/or approval of aldoxorubicin
for soft tissue sarcomas could be delayed. On July 11, 2016 the
Company issued a press release revealing that the Phase 3 clinical
trial of aldoxorubicin did not show any improvement from other
commonly used cancer drugs and that nearly half of the patients in
the Phase 3 trial were excluded from the data since the study was
disturbed by a partial clinical hold on November 2014. When this
news was disclosed, shares of CytRx dropped in value sharply,
causing investors harm.
Goldberg Law PC represents shareholders around the world and
specializes in securities class actions and shareholder rights
litigation.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and ethical rules.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160812005497/en/
Goldberg Law PC, Los AngelesMichael Goldberg, Esq.,
800-977-7401Brian Schall, Esq.,
800-977-7401info@goldberglawpc.comwww.Goldberglawpc.com
Cytrx (NASDAQ:CYTR)
Historical Stock Chart
From Apr 2024 to May 2024
Cytrx (NASDAQ:CYTR)
Historical Stock Chart
From May 2023 to May 2024